A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

A Mocroft; P Reiss; A Rakhmanova; D Banhegyi; A N Phillips; S De Wit; M Ristola; J D Lundgren; J Grarup; O Kirk; EuroSIDA in EuroCoord

doi:10.1007/s15010-014-0630-4

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

A Mocroft, P Reiss, A Rakhmanova, D Banhegyi, A N Phillips, S De Wit, M Ristola, J D Lundgren, J Grarup, O Kirk, EuroSIDA in EuroCoord

Department of Clinical Medicine

5 Citations (Scopus)

Abstract

ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

Original language	English
Journal	Infection: A Journal of Infectious Diseases
Volume	42
Issue number	4
Pages (from-to)	757-762
Number of pages	6
ISSN	0300-8126
DOIs	https://doi.org/10.1007/s15010-014-0630-4
Publication status	Published - 1 Aug 2014

Keywords

Adenine
Adult
Anti-HIV Agents
Cohort Studies
Data Collection
Deoxycytidine
Drug Combinations
Drug Utilization
Europe
Female
HIV Infections
Humans
Male
Organophosphonates
Oxazines
Prospective Studies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s15010-014-0630-4

Cite this

Mocroft, A., Reiss, P., Rakhmanova, A., Banhegyi, D., Phillips, A. N., De Wit, S., Ristola, M., Lundgren, J. D., Grarup, J., Kirk, O., & EuroSIDA in EuroCoord (2014). A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection: A Journal of Infectious Diseases, 42(4), 757-762. https://doi.org/10.1007/s15010-014-0630-4

@article{380793d54f4e4f50838e63a54fdec1c0,

title = "A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe",

abstract = "ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.",

keywords = "Adenine, Adult, Anti-HIV Agents, Cohort Studies, Data Collection, Deoxycytidine, Drug Combinations, Drug Utilization, Europe, Female, HIV Infections, Humans, Male, Organophosphonates, Oxazines, Prospective Studies",

author = "A Mocroft and P Reiss and A Rakhmanova and D Banhegyi and Phillips, {A N} and {De Wit}, S and M Ristola and Lundgren, {J D} and J Grarup and O Kirk and {EuroSIDA in EuroCoord}",

year = "2014",

month = aug,

day = "1",

doi = "10.1007/s15010-014-0630-4",

language = "English",

volume = "42",

pages = "757--762",

journal = "Infection: A Journal of Infectious Diseases",

issn = "0300-8126",

publisher = "Springer Medizin",

number = "4",

}

TY - JOUR

T1 - A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

AU - Mocroft, A

AU - Reiss, P

AU - Rakhmanova, A

AU - Banhegyi, D

AU - Phillips, A N

AU - De Wit, S

AU - Ristola, M

AU - Lundgren, J D

AU - Grarup, J

AU - Kirk, O

AU - EuroSIDA in EuroCoord

PY - 2014/8/1

Y1 - 2014/8/1

N2 - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

AB - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

KW - Adenine

KW - Adult

KW - Anti-HIV Agents

KW - Cohort Studies

KW - Data Collection

KW - Deoxycytidine

KW - Drug Combinations

KW - Drug Utilization

KW - Europe

KW - Female

KW - HIV Infections

KW - Humans

KW - Male

KW - Organophosphonates

KW - Oxazines

KW - Prospective Studies

U2 - 10.1007/s15010-014-0630-4

DO - 10.1007/s15010-014-0630-4

M3 - Journal article

C2 - 24902520

SN - 0300-8126

VL - 42

SP - 757

EP - 762

JO - Infection: A Journal of Infectious Diseases

JF - Infection: A Journal of Infectious Diseases

IS - 4

ER -

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this